Evolving molecular subtyping of breast cancer advances precision treatment.

This article explores the significance of molecular subtyping in breast cancer treatment. It discusses the different subtypes of breast cancer, including triple-negative breast cancer (TNBC), HR+/HER2- breast cancer, and HER2+ breast cancer. The authors emphasize the importance of clinical trials in validating precision treatment strategies based on molecular subtyping. They also discuss the potential of noninvasive methods, such as liquid biopsies, in improving patient compliance. The article concludes by highlighting the need for further research and clinical studies to enhance treatment efficacy. [Extracted from the article]